Search

Researchers from the Department of Urology in Shanghai, China, have published a study on papillary renal cell carcinoma (pRCC) progression and its sensitivity to gemcitabine therapy. The study found that KH-type splicing regulatory protein (KHSRP) plays a role in pRCC progression and metastasis. Inhibiting KHSRP showed promising results in reducing cellular migration, invasion, and proliferation, with UGS nanoparticles demonstrating better efficacy than gemcitabine alone. The research suggests that targeting KHSRP could be a potential therapeutic strategy for pRCC treatment. [Extracted from the article]

The article discusses a phase III clinical trial comparing perioperative and adjuvant systemic therapy for patients with resectable non-small cell lung cancer. The trial aims to determine the effectiveness of chemotherapy and immunotherapy before and after surgery compared to standard therapy given after surgery. The study will evaluate outcomes such as real-world event-free survival, overall survival, rates of surgical resection, complete resection, adverse events, and pathological complete response. The trial is not yet recruiting and will enroll 1100 participants, with a completion date of April 30, 2030. [Extracted from the article]

The article discusses a Phase 2 clinical trial, NCT06632951, evaluating the use of livmoniplimab in combination with budigalimab versus chemotherapy in subjects with metastatic urothelial carcinoma. The study aims to assess the optimized dose, adverse events, and efficacy of the investigational drugs. Approximately 150 adult participants will be enrolled across 56 sites worldwide, with three treatment arms and a study duration of up to 3.5 years. The trial may involve a higher treatment burden compared to standard care, with participants undergoing regular visits, medical assessments, and scans. [Extracted from the article]

A study conducted at Nanjing Xiaozhuang University in China has found that gemcitabine, a chemotherapeutic drug commonly used for pancreatic cancer, often becomes ineffective due to the development of resistance. The researchers used a pancreatic cancer stem cell model to test the effectiveness of various drugs in combination with gemcitabine. They found that combinations of sorafenib or sunitinib with gemcitabine showed the most promise in resensitizing gemcitabine-resistant cancer cells. The study also identified NANOG, a stemness biomarker, as a potential therapeutic biomarker for predicting effective combination treatments with gemcitabine in pancreatic cancer. [Extracted from the article]

This document provides information about a clinical trial, NCT06621095, which aims to explore the efficacy and safety of anlotinib combined with benmelstobart and AG as a first-line treatment for metastatic pancreatic cancer. The trial plans to recruit 104 participants who will be randomly assigned to either the experimental or control group. The study will evaluate the effectiveness and safety of the combination treatment, offering a potential new option for patients with advanced metastatic pancreatic cancer. The trial is being conducted in China, and the primary investigator's contact information is provided. [Extracted from the article]

A meta-analysis conducted by researchers at Ankara University School of Medicine examined the use of platinum chemotherapy combinations with immunotherapy in the treatment of metastatic urothelial carcinoma (mUC). The study found that the combination of cisplatin-gemcitabine with immunotherapy showed significant overall survival benefits compared to platinum-gemcitabine therapy. However, neither the cisplatin-gemcitabine plus immunotherapy nor the carboplatin-gemcitabine plus immunotherapy combinations demonstrated an objective response rate benefit. The researchers concluded that further research is needed to understand the exact mechanisms behind these outcomes. [Extracted from the article]

A recent report from Taichung Veterans General Hospital in Taiwan discusses the treatment of metastatic pancreatic acinar cell carcinoma (PACC) using a combination of liposomal irinotecan and S-1. PACC is a rare form of pancreatic cancer, and there is currently no standardized chemotherapy regimen for this type of cancer. The report presents a case of a patient with PACC who experienced disease progression after surgery and chemoradiotherapy, but showed positive results with the liposomal irinotecan and S-1 combination treatment. The patient remained free of recurrence and progression during a follow-up period of 2 years and 3 months. [Extracted from the article]

A recent study conducted in Chiba, Japan compared two neoadjuvant treatments for borderline resectable pancreatic cancer (BRPC): gemcitabine plus nab-paclitaxel and concurrent chemoradiotherapy with S-1. The study aimed to determine which treatment could become the standard neoadjuvant therapy for BRPC. The results showed that there was no statistically significant difference in overall survival between the two treatments, but a delayed survival advantage was observed with concurrent chemoradiotherapy with S-1. Further analysis with longer-term data is planned to confirm this advantage. [Extracted from the article]

A recent study conducted at the University of Southern California focused on pancreatic cancer, specifically Pancreatic Adenocarcinoma (PDAC). The study highlighted the challenges associated with treating PDAC, including late-stage diagnosis, poor vascularization, and resistance to chemotherapy. The researchers developed and tested novel gemcitabine analogs in patient-derived organoid models, which showed increased effectiveness in softer matrices. Additionally, the combination of gemcitabine analogs and AZD 1775, a WEE1 inhibitor, demonstrated promising results in increasing treatment effectiveness, particularly in chemoresistant cells. Further studies will explore the influence of the tumor microenvironment and genetic differences on treatment response. [Extracted from the article]

A recent study conducted at the Osaka International Cancer Institute has found that the expression of the antiapoptotic protein Mcl-1 is frequently observed in pancreatic cancer. The study evaluated the association between the therapeutic effects of gemcitabine plus nab-paclitaxel (GnP) chemotherapy and Mcl-1 expression in tissue samples obtained from patients with metastatic pancreatic cancer. The results showed that patients with higher Mcl-1 expression had a significantly higher disease control rate, longer progression-free survival, and longer overall survival compared to those with lower Mcl-1 expression. The study suggests that Mcl-1 expression could be a predictive marker for a favorable response to GnP chemotherapy. [Extracted from the article]

A recent study conducted at Jagiellonian University Medical College in Krakow, Poland, explored the potential of combining the drugs Gemcitabine (GC) and Withaferin A (WFA) for the treatment of pancreatic cancer. The researchers found that both compounds effectively inhibited cell proliferation and induced apoptosis in pancreatic cancer cell lines. The combination treatment showed the most significant inhibition of cell migration. The study also highlighted a mechanism involving increased levels of reactive oxygen species (ROS) and modulation of NF-kB activity. These findings suggest that the combination of GC and WFA may offer a synergistic therapeutic approach for treating pancreatic cancer. [Extracted from the article]

A study conducted by researchers from the University of Alabama Birmingham has found that inhibiting the BET protein can decrease the expression of HMGCS2, an enzyme involved in cholesterol biosynthesis, and sensitize pancreatic tumors to the chemotherapy drug gemcitabine. The study used a unique pancreatic cancer model with acquired resistance to gemcitabine to identify the upregulation of the cholesterol biosynthesis pathway in resistant tumors. The researchers suggest that targeting HMGCS2 could be a potential therapeutic strategy for treating gemcitabine-resistant pancreatic ductal adenocarcinoma. The study has been peer-reviewed and published in Cancer Letters. [Extracted from the article]

A study conducted by researchers at Western University in Canada has explored the effects of inhibiting endogenous hydrogen sulfide (H2S) production on bladder cancer. The researchers targeted the H2S-producing enzyme in bladder cancer cells and found that inhibiting H2S production significantly reduced cell viability and tumor growth. Additionally, the study found that inhibiting H2S production enhanced the anti-cancer effects of conventional chemotherapy. These findings suggest that inhibiting H2S production could be a novel pharmacological target for improving bladder cancer diagnosis and treatment. [Extracted from the article]

A Phase II clinical trial, NCT06597565, is currently underway to study the combination therapy of ACR-368 and gemcitabine in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). The trial aims to determine the effectiveness and safety of this treatment. Participants will receive ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week cycles. The study is currently recruiting participants and is expected to be completed by August 2028. The trial is being conducted in the United States and is sponsored by Acrivon Therapeutics in collaboration with the H. Lee Moffitt Cancer Center and Research Institute. [Extracted from the article]

A study conducted by researchers at Ajou University in Suwon, South Korea compared the survival rates of patients with recurrent glioblastoma who received bevacizumab monotherapy versus bevacizumab plus irinotecan combination therapy. The study analyzed a nationwide population-based dataset and found no significant difference in overall survival between the two treatment groups. The researchers concluded that bevacizumab monotherapy could be a suitable treatment option for recurrent glioblastoma, considering the potential additional toxicity associated with irinotecan. This study provides valuable insights for treating this type of cancer. [Extracted from the article]

This article provides information about a clinical trial (NCT06608927) conducted by Arcus Biosciences, Inc. The trial aims to compare the overall survival of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who receive different treatments. The trial has two arms: an experimental arm (Arm A) where patients receive Quemliclustat, nab-paclitaxel, and gemcitabine, and a comparator arm (Arm B) where patients receive a placebo, nab-paclitaxel, and gemcitabine. The trial is not yet recruiting and is expected to enroll 610 participants. The primary completion date for data collection is November 30, 2030. The trial is open to all genders and individuals aged 18 years and older. Inquiries can be made to Arcus Biosciences, Inc. The trial is sponsored by Arcus Biosciences, Inc. and collaborates with Taiho Pharmaceutical Co., Ltd. The trial is regulated by the U.S. FDA and data may be shared with qualified researchers upon request. [Extracted from the article]

Researchers at the University of Science and Technology China have developed a nanovaccine that shows promise in overcoming drug resistance in triple-negative breast cancer. The nanovaccine is loaded with antigens from gemcitabine-resistant tumor cells and has been found to activate immune responses and inhibit tumor growth in mice. When combined with immunotherapy, the nanovaccine's efficacy is further improved. This research presents a new strategy for overcoming drug resistance using cancer nanovaccines and has potential for broadening clinical applications. [Extracted from the article]

A report from China Pharmaceutical University discusses the development of a drug delivery system for pancreatic cancer therapy. The researchers designed pH-sensitive liposomes loaded with gemcitabine (GEM) and coated with fucoidan (FU) to enhance the effectiveness of the treatment. The results showed that the liposomes had stable structure and released the drug more quickly under acidic conditions. The study demonstrated that this drug delivery system could improve the bioavailability of GEM, making it a promising approach for pancreatic cancer treatment. [Extracted from the article]

A recent report discusses research conducted at the Royal Melbourne Hospital in Parkville, Australia, on the treatment of metastatic prostate cancer. The study focused on a patient with bone metastases who had not responded to standard therapies. The patient received a combination of Lu-177-prostate-specific membrane antigen and olaparib radiosensitization, resulting in a significant decrease in serum PSA levels. However, the treatment also caused severe marrow radiotoxicity, requiring hospitalization. The researchers concluded that radiosensitizing agents must be carefully considered and balanced in treatment planning. [Extracted from the article]

A recent study conducted at Western University explored the role of cancer-associated fibroblasts (CAFs) in pancreatic adenocarcinoma (PDAC) and their impact on treatment resistance. The researchers hypothesized that CAFs secrete factors that lead to increased therapy resistance in pancreatic cancer cells through epigenetic reprogramming. Patient-derived organoids (PDOs) and CAFs were used to examine the effects of CAFs on PDOs, and it was found that exposure to CAF-conditioned media resulted in altered phenotypes and molecular profiles of PDOs, as well as increased resistance to chemotherapy and radiotherapy. The study highlights the importance of considering the tumor microenvironment when developing therapeutic strategies for PDAC. [Extracted from the article]

A recent study conducted at University College London (UCL) has explored the use of a technique called Photochemical Internalisation (PCI) to enhance the effectiveness of chemotherapy for pancreatic cancer. The researchers aimed to improve drug delivery to the target sites and overcome multidrug resistance. The study found that PCI, which combines low dose Photodynamic Therapy (PDT) with chemotherapy, resulted in efficient delivery of therapeutic compounds to specific subcellular targets. The researchers observed minimal cytotoxicity with monotherapies, but PCI synergistically enhanced the cytotoxicity of the drugs. This study demonstrates the potential of PCI to enhance cancer chemotherapy for pancreatic cancer and may lead to better treatments in the future. [Extracted from the article]

Researchers from Incheon National University in South Korea have conducted a study on the effects of high-dose extracellular citrate treatment in pancreatic cancer cells. The study found that extracellular sodium citrate reduced cell viability and migration of pancreatic cancer cells, and also decreased the levels of a stem cell marker. Additionally, the combination of gemcitabine and extracellular sodium citrate showed a synergistic anticancer effect. The researchers suggest that this treatment approach may represent a novel therapeutic strategy for treating pancreatic cancer. [Extracted from the article]

New research from the Karolinska Institute explores the resistance of pancreatic ductal adenocarcinoma (PDAC) to conventional chemotherapy and radiation therapy. The study focuses on the communication between tumor cells and cancer-associated fibroblasts (CAFs) in the dense desmoplastic stroma, which contributes to the aggressive nature of the disease. The researchers found that CCN1, a protein, plays a role in gemcitabine sensitivity in pancreatic cancer cells. They also observed that stimulation with TGF-b1 and lysophosphatidic acid increased CCN1 expression in the tumor cells and induced a shift in CAFs towards a more myofibroblastic phenotype. This study provides valuable insights into potential therapeutic targets for pancreatic cancer treatment. [Extracted from the article]

A recent report from the University of California discusses the challenges of treating pancreatic ductal adenocarcinoma (PDA), a deadly form of pancreatic cancer. The study focuses on gemcitabine, a commonly used chemotherapy drug for PDA, and the resistance that often develops to this treatment. The researchers found that gemcitabine-resistant cells were highly susceptible to statins, a class of drugs used to lower cholesterol. They discovered that statins induce apoptosis, or cell death, in gemcitabine-resistant cells by reducing the geranylation of small GTPases. The researchers suggest that combining gemcitabine with statins could potentially improve survival rates for PDA patients. [Extracted from the article]

A patent application has been submitted for the development of a PRMT-targeting therapy to enhance the efficacy of EGFR-targeting drugs in the treatment of non-small cell lung cancer (NSCLC). The inventors propose a method of treating cancer by administering a type I PRMT inhibitor to subjects with elevated STAT1 activity, either alone or in combination with a STAT1 activating compound. The patent application includes claims related to the structure of the PRMT inhibitor, the types of cancer that can be treated, and the presence of specific genetic mutations or tumor characteristics in the subject. This research aims to address the challenge of incomplete killing of cancer cells and the development of treatment-resistant populations of cells. [Extracted from the article]

A recent study conducted by researchers at the University of Porto in Portugal has identified darifenacin, a muscarinic receptor antagonist, as a potential inhibitor of Chitinase 3-like 1 (CHI3L1) in pancreatic ductal adenocarcinoma (PDAC). The researchers used docking analysis to identify darifenacin as a promising CHI3L1 inhibitor and found that it inhibited the growth of PDAC cells while showing no cytotoxicity against normal pancreatic cells. Additionally, darifenacin sensitized PDAC cells to standard chemotherapies and decreased Akt phosphorylation. The study suggests that darifenacin has the potential to be a chemosensitizer for PDAC treatment. [Extracted from the article]

A recent study conducted by researchers at Yonsei University College of Medicine in Seoul, South Korea, examined the short-term outcomes of using intravesical gemcitabine as a treatment for non-muscle-invasive bladder cancer (NMIBC). The study included 60 patients with high- or very high-risk NMIBC who received weekly intravesical gemcitabine for 6 weeks after transurethral resection of bladder tumor (TURBT). The study found that there was a similar disease-free survival (DFS) outcome between high-risk and very high-risk patients in the short-term. However, the researchers noted that further studies with more patients and long-term outcomes are needed to confirm these findings. [Extracted from the article]

Researchers at the Second Affiliated Hospital of Nanchang University have conducted a study on pancreatic cancer and its resistance to gemcitabine chemotherapy. The study found that the deubiquitinase STAMBP is significantly upregulated in pancreatic cancer tissues, and its knockdown increases sensitivity to gemcitabine in pancreatic cancer cells. The researchers also discovered that STAMBP promotes the Warburg effect and chemotherapy resistance by modulating E2F1 via direct binding. Additionally, they identified the FDA drug entrectinib as a potent gemcitabine sensitizer and STAMBP inhibitor. This study provides insights into the mechanisms of chemotherapy resistance in pancreatic cancer and offers a potential target for treatment. [Extracted from the article]

A systematic review and network meta-analysis conducted by researchers from Chang Gung University in Taiwan compared the efficacy of different first-line combination therapies for advanced pancreatic cancer. The study analyzed data from 46 randomized clinical trials involving 10,499 patients and found that gemcitabine-based or fluorouracil-based triplet or quadruplet regimens, such as gemcitabine+nab-paclitaxel and FOLFIRINOX, were associated with superior overall survival and progression-free survival compared to gemcitabine monotherapy. However, the addition of targeted drugs, monoclonal antibodies, or other medications did not improve survival outcomes. The researchers suggest further research to explore the potential benefits of adding chemotherapy agents to the gemcitabine-based doublet regimen. [Extracted from the article]

A recent study conducted at Shanxi Medical University in Taiyuan, China, has explored a new approach to treating solid tumors using a combination of radionuclide therapy (RNT) and chemotherapy. The researchers developed an injectable hydrogel containing gold nanoparticles and the anticancer drug gemcitabine, which enhanced the effectiveness of RNT by increasing the dose deposited in tumor cells and inhibiting the repair of radioactive damage to cellular DNA. The hydrogel demonstrated excellent biosecurity and stability in radionuclide labeling, and it was found to significantly inhibit the growth of triple-negative breast cancer in both in vivo and in vitro experiments. This integrated therapeutic strategy shows promise for advancing radionuclide therapy in the clinical treatment of cancer. [Extracted from the article]

A recent study conducted at Shahid Beheshti University focused on the development of an effective drug delivery system for irinotecan hydrochloride, a commonly used treatment for colorectal cancer and lung cancers involving small cells. The researchers utilized a novel method called Expansion Supercritical Fluid to create polyethylene glycolylated (PEGylated) liposomes carrying the drug. Through optimization of operating parameters, the researchers achieved high encapsulation efficiency, small liposome size, and a stable drug release profile. This research offers potential advancements in cancer gene therapy and drug delivery systems. [Extracted from the article]

A recent study conducted at the University of Birmingham in the United Kingdom has found that local delivery of the drug irinotecan to patients with recurrent glioblastomas during reoperation is a safe method of administration. Glioblastomas are difficult to completely remove and often recur at the margins of the resection. Systemic treatment is hindered by the blood-brain barrier, so the researchers explored the intraparenchymal injection of irinotecan into the resection cavity. The study showed that irinotecan administration resulted in a median survival of 32.6 weeks and a median overall survival of 30.5 months, with a two-year survival rate of 56%. This research suggests that local delivery of irinotecan may be a promising treatment option for recurrent glioblastoma patients. [Extracted from the article]

A recent study conducted in Singapore explored the use of immune checkpoint inhibitors in combination with chemotherapy for patients with triple-negative breast cancer (TNBC). The study found that adding atezolizumab, an immune checkpoint inhibitor, to chemotherapy did not improve overall survival in patients with TNBC relapsing within 12 months. The researchers concluded that a better understanding of the biology of TNBC is needed to develop more effective therapies for these patients. The study was supported by Hoffmann-La Roche and has been published in the Annals of Oncology. [Extracted from the article]

This document provides information about a clinical trial for the treatment of pancreatic cancer. The trial aims to evaluate the effectiveness and safety of a combination therapy involving antiviral and anticancer drugs. It is open to individuals between the ages of 18 and 75 who have advanced pancreatic cancer and have not received previous treatment. The trial is currently in the recruitment phase and interested individuals can find contact information for participation. [Extracted from the article]

The article presents the discussion on study on the pharmacokinetics of liposomal irinotecan, a drug used for treating various cancers, highlighting new methods to accurately measure its concentration in human plasma. Topics include the development of specific bioanalytical methods for quantifying encapsulated and non-encapsulated drug forms, the impact of cryoprotectants on drug stability; and the application of these methods in clinical trials for pediatric cancer patients.

A recent study conducted by researchers at the University of Washington has found that a drug combination of gemcitabine and paclitaxel, delivered through nanoparticles, can effectively regress breast tumors. The researchers discovered that the nanoparticles were taken up rapidly by the lymphatic system, leading to enhanced co-localization of the drugs within the tumors. This resulted in significant tumor growth inhibition and regression. The study suggests that this synchronized delivery method offers improved efficacy and cellular retention. Further research is needed to explore the potential of this drug combination in suppressing human breast tumor growth. [Extracted from the article]

This document provides information about a clinical trial, NCT06567600, for the treatment of intrahepatic cholangiocarcinoma, a type of liver cancer. The trial aims to evaluate the effectiveness and safety of combining low-dose gemcitabine and cisplatin chemotherapy with the immune checkpoint inhibitor PD-1/PD-L1 antibody. The study is based on the hypothesis that low-dose chemotherapy can enhance the immune response to immunotherapy while minimizing side effects. The trial is not yet recruiting participants and is being conducted in China, with the Second Affiliated Hospital of Guangzhou Medical University as a collaborator. The primary completion date is December 31, 2027, and the contact person for the study is Ye Linsen. [Extracted from the article]

A study conducted by researchers at Fudan University explored the effectiveness of immunotherapy in the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC). The study involved a combination treatment regimen of tislelizumab, cetuximab, and irinotecan in 33 patients who had previously undergone two lines of therapy. The primary endpoint of the study, a confirmed objective response rate of 33%, was met. The secondary endpoints included a disease control rate of 79% and median progression-free survival and overall survival of 7.3 and 17.4 months, respectively. The study demonstrated the antitumor activity of the combination treatment with a tolerable safety profile in previously treated MSS and RAS wild-type mCRC. [Extracted from the article]

A recent study conducted by researchers at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, explores the immunosenescence-related microenvironment in pancreatic cancer. The study identifies two immunosenescence-associated isoforms (IMSP1 and IMSP2) that have different prognostic implications and immune cell infiltration. The researchers developed a hazard score system called MLIRS, based on machine learning algorithms, which showed robust prognostic performance. The study also identified a windsock called GLUT1 that contributes to gemcitabine resistance in pancreatic cancer cells. This research provides valuable insights into the immunosenescence microenvironment and offers potential directions for clinical prediction and application. [Extracted from the article]

A recent study conducted by researchers at the University of Santiago de Compostela in Spain has focused on pancreatic cancer, which is known to be one of the most deadly forms of cancer. The researchers aimed to address the limitations of chemotherapy, such as poor targeting and systemic toxicity, by developing a new drug delivery system. They successfully encapsulated the anticancer drug gemcitabine in self-assembled copolymer micelles, which were then modified with pancreatic cancer cell membrane to improve targeting properties. The study highlights the potential of this innovative nanotherapy approach for pancreatic cancer treatment. [Extracted from the article]

This document provides information about a clinical trial, NCT06569225, that aims to investigate the use of perioperative therapy with Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig for patients with resectable intrahepatic cholangiocarcinoma (iCCA), a type of liver cancer. The trial aims to optimize perioperative treatment to reduce recurrence and improve outcomes in patients with resectable biliary tract cancer. The trial is not yet recruiting participants and aims to enroll 40 patients. The study will continue for 12 months, with a completion date of December 31, 2028. The document also includes eligibility criteria for participants and administrative information about the trial. [Extracted from the article]

The article focuses on a clinical trial investigating the effectiveness of drug gemcitabine/cisplatin plus cemiplimab, with or without fianlimab, in treating bladder cancer. It explains that participants are randomly assigned to receive either the full regimen or a combination without fianlimab, followed by a series of treatments and evaluations, including repeat tumor resections and imaging.

The article focuses on a clinical trial investigating the use of genetic and protein data from tumors to guide treatment for pancreatic ductal adenocarcinoma (PDAC). Topics include assessing the feasibility of timely genetic testing for treatment decisions, determining how genetic information predicts treatment response or resistance, and evaluating the role of genetic and protein data in personalized treatment strategies.

The article reports on a new study by the National Health and Medical Research Council Clinical Trials Centre that explores the efficacy of drug, LSTA1 combined with gemcitabine and nab-paclitaxel in treating pancreatic cancer. Topics discussed include the study's methodology, the results showing a high disease control rate, and the trial's endpoints focusing on progression-free survival and biomarkers.